Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
19 Dezember 2008 - 11:42PM
PR Newswire (US)
NEW BRUNSWICK, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Johnson
& Johnson (NYSE:JNJ) today announced it has extended its
previously announced cash tender offer, through its wholly-owned
subsidiary, Binder Merger Sub, Inc., for all outstanding shares of
common stock of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI) until
12:00 midnight (Eastern time), on Dec. 26, 2008, unless further
extended. The tender offer was originally scheduled to expire at
12:00 midnight (Eastern time) on Dec. 23, 2008. All other terms and
conditions of the tender offer remain unchanged. As previously
disclosed, the conditions to the tender offer relating to Israeli
antitrust approval and other regulatory approvals have been
satisfied. The depositary for the tender offer has advised Johnson
& Johnson that, as of 3:00 p.m. (Eastern time) today, a total
of approximately 4,101,234 shares of Omrix common stock were
validly tendered and not withdrawn (including approximately 2,000
shares subject to guaranteed delivery procedures), representing
approximately 23.4% of Omrix's common stock on a fully diluted
basis. Upon the successful closing of the tender offer,
stockholders of Omrix will receive $25.00 in cash for each share of
Omrix common stock tendered in the tender offer, less any required
withholding taxes. Following the completion of the acquisition, it
is expected that Omrix will operate as a stand-alone entity
reporting through ETHICON, Inc, a Johnson & Johnson company.
About Johnson & Johnson Caring for the world, one person at a
time...inspires and unites the people of Johnson & Johnson. We
embrace research and science - bringing innovative ideas, products
and services to advance the health and well-being of people. Our
119,400 employees at more than 250 Johnson & Johnson companies
work with partners in health care to touch the lives of over a
billion people every day, throughout the world. Additional
Information This press release is neither an offer to purchase nor
a solicitation of an offer to sell shares of Omrix
Biopharmaceuticals, Inc. Johnson & Johnson and Binder Merger
Sub, Inc. have filed a tender offer statement with the Securities
and Exchange Commission ("SEC"), and have mailed an offer to
purchase, forms of letter of transmittal and related documents to
Omrix stockholders. Omrix has filed with the SEC, and has mailed to
Omrix stockholders, a solicitation/recommendation statement on
Schedule 14D-9. These documents contain important information about
the tender offer and stockholders of Omrix are urged to read them
carefully. These documents are available at no charge at the SEC's
website at http://www.sec.gov/. The tender offer statement and the
related materials may be obtained for free by directing a request
by mail to Georgeson Inc., 199 Water Street, New York, New York
10038 or by calling toll-free (888) 679-2897. In addition, a copy
of the offer to purchase, letter of transmittal and certain other
related tender offer documents may be obtained free of charge by
directing a request to Johnson & Johnson at
http://www.jnj.com/, or Johnson & Johnson, One Johnson &
Johnson Plaza, New Brunswick, NJ 08933, Attn: Corporate Secretary's
Office. DATASOURCE: Johnson & Johnson CONTACT: Press - Jeffrey
J. Leebaw, +1-732-524-3350, +1-732-642-6608 M, Bill Price,
+1-732-524-6623, +1-732-668-3735 M, Investors: Louise Mehrotra,
+1-732-524-6491, or Stan Panasewicz, +1-732-524-2524 Web Site:
http://www.jnj.com/
Copyright
Omrix Biopharmaceuticals (MM) (NASDAQ:OMRI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Omrix Biopharmaceuticals (MM) (NASDAQ:OMRI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024